← SynDRA
CARMOFUR
SynDRA canonical compound SYN0011892 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | TYMS |
|---|
| Mechanism of action | Thymidylate synthase inhibitor |
|---|
| Indication | breast cancer | colorectal cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- TYMS
- ASAH1
- Asah1
- CYP2D6
- Faah
- MAPK3
- REP
- SQOR
Mechanisms of action (all sources)
- thymidylate synthase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NR1I2
- ABL1
- KCNH2
- NPY1R
- MMP9
- MMP1
- MLNR
- MC5R
- MC4R
- MC3R
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HMGCR
- HDAC6
- GSK3B
- GHSR
- NPY2R
- NR3C1
- ACHE
- SLC29A1
- TRIM24
- TDP1
- TBXAS1
- TBXA2R
- TACR2
- TACR1
- SMN1
- SLCO1B3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATAD5
- CP2C9
- CP2CJ
- CP2D6
- CP3A4
- IFNG
- KSYK
- NSD2
- SYK
- TP53
Drug classes
ATC classes
Cross-references
Synonyms
- 1-hexylcarbamoyl-5-fluorouracil
- mifurol
- yamaful
- Mifurol
- NSC-758963
- Hexylcarbamoyl fluorouracil
- HCFU
- Yamaful
- 1-Hexylcarbamoyl-5-fluorouracil
- 5-fluoro-N-hexyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-carboxamide
- 1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo-
- NSC 758963
- HA82M3RAB2
- 5-fluoro-N-hexyl-2,4-dioxopyrimidine-1-carboxamide
- NCGC00095165-01
- Carmofurum
- Carmofur [INN:JAN]
- Carmofurum [INN-Latin]
- SMR000466363
- Mifurol (TN)
- CAS-61422-45-5
- CCRIS 2759
- Uracil, 5-fluoro-1-hexylcarbamoyl-
- 5-fluoro-1-(n-hexylcarbamoyl)uracil
- UNII-HA82M3RAB2
- BRN 0888898
- Yamafur
- HCFU; Mifurol
- Carmofur,(S)
- CPD000466363
- CARMOFUR [INN]
- CARMOFUR [JAN]
- CARMOFUR [MI]
- Spectrum2_000026
- Spectrum3_001960
- Carmofur (JP17/INN)
- 2,4-Dioxo-5-fluoro-N-hexyl-1,2,3,4-tetrahydro-1-pyrimidinecarboxamide
- 2,4-Dioxo-5-fluoro-N-hexyl-3,4-dihydro-1(2H)-pyrimidinecarboxamidme
Look up CARMOFUR in the interactive SynDRA portal →